Epigenetic biomarkers in skin cancer

被引:48
|
作者
Greenberg, Edward S. [1 ]
Chong, Kelly K. [1 ]
Huynh, Kelly T. [1 ]
Tanaka, Ryo [1 ]
Hoon, Dave S. B. [1 ]
机构
[1] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA
基金
美国国家卫生研究院;
关键词
Epigenetics; Biomarker; Methylation; MicroRNA; Melanoma; Prognosis; ISLAND METHYLATOR PHENOTYPE; MELANOMA-CELL PROLIFERATION; ABERRANT DNA METHYLATION; TUMOR-SUPPRESSOR GENES; REAL-TIME PCR; DOWN-REGULATION; CUTANEOUS MELANOMA; PROMOTER HYPERMETHYLATION; CIRCULATING MICRORNAS; PERIPHERAL-BLOOD;
D O I
10.1016/j.canlet.2012.01.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epigenetic aberrations have been associated with cutaneous melanoma tumorigenesis and progression including dysregulated DNA gene promoter region methylation, histone modification, and microRNA. Several of these major epigenetic aberrations have been developed into biomarkers. Epigenetic biomarkers can be detected in tissue and in blood as circulating DNA in melanoma patients. There is strong evidence that biomarkers in cutaneous melanoma will have an important role as companions to therapeutics and overall patient management. Important progress has been made in epigenetic melanoma biomarker development and verification of clinical utility, and this review discusses some of the key current developments and existing challenges. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:170 / 177
页数:8
相关论文
共 50 条
  • [41] Current insights into the epigenetic mechanisms of skin cancer
    Sang, Yanqi
    Deng, Yu
    DERMATOLOGIC THERAPY, 2019, 32 (04)
  • [42] Epigenetic biomarkers of prognosis in stage IIA colon cancer
    Pagotto, Sara
    Porcellini, Elisa
    Bacalini, Maria G.
    Sarti, Diletta
    Garajova, Ingrid
    Broseghini, Elisabetta
    Laprovitera, Noemi
    Vasuri, Francesco
    Garagnani, Paolo
    Mariani-Costantini, Renato
    Basso, Michele
    Visone, Rosa
    Larocca, Luigi M.
    Ferracin, Manuela
    Veronese, Angelo
    CANCER RESEARCH, 2018, 78 (13)
  • [43] Epigenetic biomarkers in prostate cancer: Current and future uses
    Chiam, Karen
    Ricciardelli, Carmela
    Bianco-Miotto, Tina
    CANCER LETTERS, 2014, 342 (02) : 248 - 256
  • [44] Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis
    Ajithkumar, Priyadarshana
    Vasantharajan, Sai Shyam
    Pattison, Sharon
    McCall, John L.
    Rodger, Euan J.
    Chatterjee, Aniruddha
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (02)
  • [45] Exposure and epigenetic biomarkers in studies of breast and hepatocellular cancer
    Santella, Regina M.
    MUTAGENESIS, 2009, 24 (06) : 534 - 534
  • [46] Circulating epigenetic biomarkers for detection of recurrent colorectal cancer
    Symonds, Erin L.
    Pedersen, Susanne K.
    Murray, David
    Byrne, Susan E.
    Roy, Amitesh
    Karapetis, Christos
    Hollington, Paul
    Rabbitt, Philippa
    Jones, Frederick S.
    LaPointe, Lawrence
    Segelov, Eva
    Young, Graeme P.
    CANCER, 2020, 126 (07) : 1460 - 1469
  • [47] Epigenetic Alterations as Cancer Diagnostic, Prognostic, and Predictive Biomarkers
    Deng, Dajun
    Liu, Zhaojun
    Du, Yantao
    EPIGENETICS AND CANCER, PT B, 2010, 71 : 125 - 176
  • [48] Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives
    Singh, Alka
    Gupta, Sameer
    Sachan, Manisha
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2019, 7
  • [49] Epigenetic biomarkers of colorectal cancer: Focus on DNA methylation
    Coppede, Fabio
    CANCER LETTERS, 2014, 342 (02) : 238 - 247
  • [50] Identification of candidate epigenetic biomarkers for ovarian cancer detection
    Huang, Yi-Wen
    Jansen, Rachel A.
    Fabbri, Enrica
    Potter, Dustin
    Liyanarachchi, Sandya
    Chan, Michael W. Y.
    Liu, Joseph C.
    Crijns, Anne P. G.
    Brown, Robert
    Nephew, Kenneth P.
    Van Der Zee, Ate G. J.
    Cohn, David E.
    Yan, Pearlly S.
    Huang, Tim H. -M.
    Lin, Huey-Jen L.
    ONCOLOGY REPORTS, 2009, 22 (04) : 853 - 861